{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+monotherapy",
    "query": {
      "intervention": "placebo monotherapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 426,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+monotherapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T17:28:09.015Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00090116",
      "title": "The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Neramexane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2003-03",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-05",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 34,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Fresno, California + 30 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00090116"
    },
    {
      "nct_id": "NCT00261443",
      "title": "A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Lithium or Valproate with placebo (PBO)",
          "type": "DRUG"
        },
        {
          "name": "Lithium or Valproate with Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1270,
      "start_date": "2005-09",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2023-04-18",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 29,
      "location_summary": "Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00261443"
    },
    {
      "nct_id": "NCT06598943",
      "title": "A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis",
        "Ulcerative Colitis Chronic"
      ],
      "interventions": [
        {
          "name": "Eltrekibart",
          "type": "DRUG"
        },
        {
          "name": "Mirikizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 143,
      "start_date": "2024-10-10",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 46,
      "location_summary": "Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06598943"
    },
    {
      "nct_id": "NCT00615940",
      "title": "Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "WX-671",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Heidelberg Pharma AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 132,
      "start_date": "2008-07",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2014-02-28",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 3,
      "location_summary": "New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00615940"
    },
    {
      "nct_id": "NCT07167966",
      "title": "Alzheimer's Tau Platform: Regimen A - AADvac1",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Preclinical Alzheimer's Disease",
        "Prodromal Alzheimer's Disease",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "AADvac1",
          "type": "DRUG"
        },
        {
          "name": "Donanemab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul S. Aisen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 450,
      "start_date": "2026-11-03",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07167966"
    },
    {
      "nct_id": "NCT03707990",
      "title": "A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity and Overweight"
      ],
      "interventions": [
        {
          "name": "NNC0165-1875",
          "type": "DRUG"
        },
        {
          "name": "Placebo (NNC0165-1875)",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 88,
      "start_date": "2018-10-15",
      "completion_date": "2019-08-13",
      "has_results": false,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03707990"
    },
    {
      "nct_id": "NCT00821977",
      "title": "Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Vildagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2008-11",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 141,
      "location_summary": "Pell City, Alabama • Gilbert, Arizona • Mesa, Arizona + 116 more",
      "locations": [
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821977"
    },
    {
      "nct_id": "NCT03604419",
      "title": "Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "PB-119 100 μg+ Glucophage®",
          "type": "DRUG"
        },
        {
          "name": "PB-119 150 μg+ Glucophage®",
          "type": "DRUG"
        },
        {
          "name": "PB-119 200 μg+ Glucophage®",
          "type": "DRUG"
        },
        {
          "name": "PB-119 placebo + Glucophage®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PegBio Co., Ltd.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 214,
      "start_date": "2018-06-13",
      "completion_date": "2019-07-23",
      "has_results": false,
      "last_update_posted_date": "2020-01-22",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03604419"
    },
    {
      "nct_id": "NCT07193563",
      "title": "A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Social Anxiety Disorder (SAD)"
      ],
      "interventions": [
        {
          "name": "ENX-102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Engrail Therapeutics INC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 47,
      "start_date": "2025-09-05",
      "completion_date": "2026-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07193563"
    },
    {
      "nct_id": "NCT03776175",
      "title": "A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease (NAFLD)"
      ],
      "interventions": [
        {
          "name": "PF-05221304 Monotherapy",
          "type": "DRUG"
        },
        {
          "name": "PF-06865571 Monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-05221304 and PF-06865571 Combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 99,
      "start_date": "2019-01-04",
      "completion_date": "2019-10-11",
      "has_results": true,
      "last_update_posted_date": "2020-09-23",
      "last_synced_at": "2026-09-04T17:28:09.015Z",
      "location_count": 29,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Chula Vista, California + 22 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03776175"
    }
  ]
}